Ischemic preconditioning, myocardial stunning, and hibernation: Basic aspects

American Heart Journal

Volumn 138, Issue 2 II, 1999, Pages

  Ferrari, R ^a   Ceconi, C ^a   Curello, S ^a   Percoco, G ^a   Toselli, T ^a   Antonioli, G ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; GLIBENCLAMIDE; HEAT SHOCK PROTEIN; MANGANESE SUPEROXIDE DISMUTASE;

CORONARY ARTERY DISEASE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STUNNED HEART MUSCLE;

EID: 0032777186     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70322-4     Document Type: Article

References (65)

1. Rahimtoola SH. Coronary bypass surgery for chronic angina. Circulation 1982;65:225-41.
2. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-9.
3. Reimer KA, Muray CE, Yamasawa I, et al. Four brief periods of myocardial ischemia cause no cumulative at a loss or necrosis. Am J Physiol 1986;251:H1306-15.
4. Ferrari R. The new ischemic syndromes: an old phenomenon disguises with a new glossary? Cardiovasc Res 1977;36:228-30.
5. Diamond GA, Forrester JS, deLuz PL, et al. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978;95:204-10.
6. Heyndrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after brief coronary occlusion in conscious dogs. J Clin Invest 1975;56:978-85.
7. Heusch G. Hibernating myocardium. Physiol Rev 1998;78:4.
8. Heusch G, Ferrari R, Hearse DJ, et al. "Myocardial hibernation": questions and controversies. Cardiovasc Res 1997;36:298-300.
9. Ferrari R, Ceconi C, Curello S, et al. Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc Pharmacol 1996;28(I):S18-26.
10. Mills I, Fallon JT, Wrenn D. Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow. Am J Physiol 1994;266:H447-57.
11. Chen C, Li L. Incremental doses of dobutamine induce a bisphasic response in dysfunctional left ventricular regions subtending coronary stenoses. Circulation 1995;92:756-66.
12. Chen C, Chen L, Fallon JT. Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion: a pig model of myocardial hibernation. Circulation 1996;94:507-16.
13. Hearse DJ. Myocardial ischemia: can we agree on a definition for the 21st Century? Cardiovasc Res 1994;28:1737-44.
14. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72(suppl V):V-123-35.
15. Hearse DJ. Myocardial hibernation: a form of endogenous protection? Eur Heart J 1997;18:A2-7.
16. VanOverschelde JLJ, Wijins W, Depre C, et al. Mechanisms of chronic regional post-ischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-23.
17. Marinho NVS, Keogh BE, Costa DC, et al. Pathophysiology of chronic left ventricular dysfunction: new insights from the measurements of absolute myocardial blood flow and glucose utilization. Circulation 1996;93:737-44.
18. Camici PG, Wijns W, Brogers M, et al. Pathophysiological mechanism of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997; 96:3205-14.
19. Rahimtoola SH. Hibernating myocardium has reduced blood flow at rest that increases with low-dose dobutamine. Circulation 1996; 94:3055-61.
20. Rahimtoola SH. Hibernating myocardium is hypoperfused. Basic Res Cardiol 1997;92:9-12.
21. Elsasser A, Schaper J. Hibernating myocardium: adaptation or degeneration? Basic Res Cardiol 1995;90:47-8.
22. Borges M, Ausma J. Structural aspects of the chronic hibernation myocardium. Am J Cardiol 1995;90:44-6.
23. Depre C, Vanoverschelde JJ, Melin JA. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol 1995;268:H1265-75.
24. Bristow JD, Arai AE, Anselone CG, et al. Response to myocardial ischemia as a regulated process. Circulation 1991;84:2580-7.
25. Ross J. Myocardial perfusion-contraction matching: implications for coronary heart disease and hibernation. Circulation 1991;83: 1076-83.
26. Ferrari R, Bongrazio M, Cargnoni A, et al. Heat shock protein changes in hibernation: a similarity with heart failure? J Mol Cell Cardiol 1996;28:2383-95.
27. Schulz R, Post H, Sakka S, et al. Intra-ischemic preconditioning increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion. Circ Res 1995;76:942-50.
28. Duncker DJ, Schulz R, Ferrari R, et al. "Myocardial stunning": remaining questions. Cardiovasc Res 1998;38:549-58.
29. Redwood SR, Ferrari R, Marber MS. Reversible left ventricular dysfunction: does it affect clinical practice and does it matter? Int J Clin Pract 1998;52(4):249-53.
30. Heyndrickx GR, Vatner SF, Wijns W. Stunning, hibernation and preconditioning: clinical pathophysiology of ischemia. Philadelphia: Lippincott Raven Publishers; 1997.
31. Ferrari R. Commentary on myocardial stunning and its clinical relevance. Basic Res Cardiol 1995;90:300-2.
32. Bolli R. Mechanism of myocardial "stunning." Circulation 1990;82: 723-38.
33. Bolli R. Oxygen derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther 1991;5:249-68.
34. Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy began at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res 1989;65: 607-22.
35. Bolli R, McCay PB. Use of spin traps in intact animals undergoing myocardial ischemia/reperfusion: a new approach to assessing the role of oxygen radicals in myocardial "stunning." Free Radic Res Commun 1990;9:169-80.
36. Engler RL, Covell JW. Granulocytes cause reperfusion ventricular dysfunction after 15 min ischemia on the dog. Circ Res 1987;61:20-8.
37. Bolli R. Role of neutrophils in myocardial stunning after brief ischemia: the end of a 6-year-old controversy. Cardiovasc Res 1993;27:728-30.
38. Ferrari R, Ceconi C, Curello S, et al. Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc Pharmacol 1996;28(I):S18-26.
39. Ferrari R, Alfieri O, Curello S, et al. Occurrence of oxidative stress during reperfusion of the human heart. Circulation 1990;81:201-11.
40. Harada K, Franklin A, Johnson PG, et al. Acidemia and hypernatremia enhance postischemic recovery of excitation-contraction coupling. Circ Res 1994;74:1197-209.
41. 2+ overload and depressed coronary recovery of ventricular function of reperfused ischemic rat hearts. Circ Res 1989;44:1045-56.
42. Opie LH. Myocardial stunning: a role for calcium antagonists during reperfusion? Cardiovasc Res 1992;26:20-4.
43. Ehring T, Bohm M, Heusch G. The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia. J Cardiovasc Pharmacol 1992;20:63-74.
44. Gao WD, Atar D, Liu Y, et al. Role of troponin I in the pathogenesis of stunned myocardium. Circ Res 1997;80:393-9.
45. 2+-ATPase function by direct attack on the ATP binding site. Circ Res 1997;80:76-81.
46. Ertl G, Alexander RW, Braunwald E. Interaction between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol 1983;78:518-33.
47. Przyklenk K. Angiotensin converting enzyme inhibitors. In: Kloner RA, Przyklenk K, editors. Stunned myocardium: properties, mechanisms and clinical manifestations. New York: Marcel Dekker; 1993. p 321-36.
48. Duncker DJ, Soei LK, Verdouw PD. Pharmacological modulation of myocardial stunning. In: Heyndrickx GR, Vatner SF, Wijns W, editors. Stunning, hibernation and preconditioning: clinical pathophysiology of ischemia. Philadelphia: Lippincott Raven Publishers; 1997. p 229-52.
49. Yellon DM, Baxter GF, Garcia-Dorado D, et al. Ischemia preconditioning: present position and future directions. Cardiovasc Res 1998;37:21-33.
50. Cave AC. Preconditioning induced protection against post-ischemic contractile dysfunction: characteristics and mechanisms. J Mol Cell Cardiol 1995;27:969-79.
51. Murray CE, Jennings RB, Reimer KA. New insights into potential mechanisms of ischemic preconditioning. Circulation 1991;84:442-5.
52. Reimer KA, Murry CE, Yamasawa I, et al. Four brief periods of ischemia cause no cumulative ATP loss or necrosis. Am J Physiol 1986;251:H1306-15.
53. Speechly Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77: 1030-5.
54. Armstrong S, Downey JM, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc Res 1994;28;72-7.
55. Marber MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-72.
56. Schott RJ, Rohmann S, Braun ER, et al. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990;66:1133-42.
57. Thornton J, Striplin S, Liu GS, et al. Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning. Am J Physiol 1990;259:H1822-5.
58. Thornton J, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol 1993;25:311-20.
59. Downey JM, Cohen MV. Signal transduction in ischemic preconditioning. Z Kardiol 1995;4:77-86.
60. Vahlhaus C, Schulz R, Post H, et al. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 1996;79:407-14.
61. Mizimura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release and neutrophil function in dogs. Circulation 1995;92:1236-45.
62. Yao Z, Gross GJ. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am J Physiol 1994;267:H1888-94.
63. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994;267:H 1341-52.
64. Baxter GF, Goma FM, Yellon DM. Characterization of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res Cardiol 1997;92:159-67.
65. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993;72:1293-9.